A PYMNTS Company

FTC Approves ANI Deal To Buy Novitium, With Divestments

By  |  November 10, 2021

Specialty pharmacy company ANI Pharmaceuticals Inc has won US antitrust approval to buy Novitium Pharma on condition it divest rights or assets related to two generic medicines, the Federal Trade Commission said on Wednesday.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The companies, which announced their $210 million deal in March, agreed to sell ANI’s development rights to generic sulfamethoxazole-trimethoprim oral suspension, a combination of antibiotics, and assets related to generic dexamethasone, used to treat inflammation and arthritis.

    ANI already sells the antibiotic and is well-positioned to sell the anti-inflammatory while Novitium is a potential seller of both.

    “Preserving the potential for entry ensures that the merged firm does not kill off ongoing product development efforts that could cause prices for its products to go down,” said Holly Vedova, director of the FTC’s Bureau of Competition, in a statement.

    Under the terms of the proposed order, ANI and Novitium are required to divest ANI’s rights and assets to generic SMX-TMP oral suspension and generic dexamethasone tablets to Prasco within 10 days after the acquisition is final.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.